Inventor
VAN EENENNAAM HANS
NL18 patents
⚠️ This page may combine multiple inventors who share the name “VAN EENENNAAM HANS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ADURO BIOTECH HOLDINGS EUROPE B V
12 patentsUS10377830B2Aug 13, 2019
Method of treating IgA nephropathy by administering humanized APRIL-binding antibodies
ADURO BIOTECH HOLDINGS EUROPE B V13 citations90
US9969808B2May 15, 2018
Altered APRIL binding antibodies
ADURO BIOTECH HOLDINGS EUROPE B V13 citations90
US10961316B2Mar 30, 2021
Humanized antibodies which bind to human APRIL (“a proliferation-inducing ligand”)
ADURO BIOTECH HOLDINGS EUROPE B V4 citations82
US10107821B2Oct 23, 2018
Proliferation-inducing ligand (APRIL)-binding peptides
ADURO BIOTECH HOLDINGS EUROPE B V8 citations81
US10851164B2Dec 1, 2020
Anti-SIRPα antibodies
ADURO BIOTECH HOLDINGS EUROPE B V9 citations77
US9527916B2Dec 27, 2016
Agonistic antibody to CD27
ADURO BIOTECH HOLDINGS EUROPE B V14 citations73
US11047864B2Jun 29, 2021
Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a human sample
ADURO BIOTECH HOLDINGS EUROPE B V2 citations70
US11959924B2Apr 16, 2024
Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
ADURO BIOTECH HOLDINGS EUROPE B V0 citations59
US12145992B2Nov 19, 2024
Method of treating IgA nephropathy by administering altered antibodies which bind human a proliferation-inducing ligand (APRIL) protein
ADURO BIOTECH HOLDINGS EUROPE B V0 citations57
US12168693B2Dec 17, 2024
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
ADURO BIOTECH HOLDINGS EUROPE B V0 citations51
US10808030B2Oct 20, 2020
Anti-HCTLA-4 antibodies
ADURO BIOTECH HOLDINGS EUROPE B V0 citations34
US10494436B2Dec 3, 2019
Anti-PD-1 antibodies
ADURO BIOTECH HOLDINGS EUROPE B V0 citations33